Lacritin C-terminal synthetic peptide ‘N-94/C-6’ (‘Lacripep’) is equally active on aire−/− dry eye mice [33], and in initial humans studies [phase I/II trial (NCT03226444); [39]]. This evidence concerns the gene LACRT and dry eye syndrome.